SURI vs. XPH

Last updated Jun 4, 2026

SURI (Simplify Propel Opportunities ETF) and XPH (SPDR S&P Pharmaceuticals ETF) are both Health & Biotech Equities funds. SURI is actively managed, while XPH is passively managed. Over the past 3 years, SURI returned 6.93%/yr vs 13.07%/yr for XPH. A 0.58 correlation means they provide meaningful diversification when combined. SURI charges 2.51%/yr vs 0.35%/yr for XPH.

Performance

SURI vs. XPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Simplify Propel Opportunities ETF (SURI) and SPDR S&P Pharmaceuticals ETF (XPH). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, SURI achieves a 6.10% return, which is significantly higher than XPH's 0.66% return.

SURI

• 1D: -1.15%
• 1M: -2.84%
• YTD: 6.10%
• 6M: 3.98%
• 1Y: 32.89%
• 3Y*: 6.93%
• 5Y*: —
• 10Y*: —

XPH

• 1D: 1.10%
• 1M: -4.74%
• YTD: 0.66%
• 6M: 4.44%
• 1Y: 37.98%
• 3Y*: 13.07%
• 5Y*: 3.50%
• 10Y*: 3.44%

*Multi-year figures are annualized to reflect compound growth (CAGR)

SURI vs. XPH - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
SURI Simplify Propel Opportunities ETF	6.10%	28.32%	-13.34%	-2.87%
XPH SPDR S&P Pharmaceuticals ETF	0.66%	31.60%	4.94%	-2.89%

Correlation

The correlation between SURI and XPH is 0.53, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.53
Correlation (3Y) Calculated over the trailing 3-year period	0.57
Correlation (All Time) Calculated using the full available price history since Feb 9, 2023	0.58

The correlation between SURI and XPH has been stable across timeframes, ranging from 0.53 to 0.58 - a consistent structural relationship.

SURI vs. XPH - Sectors Allocation Comparison

Sectors	SURI	XPH
Healthcare	56.4%	100.0%
Energy	43.6%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Financial Services	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

SURI vs. XPH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SURI

SURI Risk / Return Rank: 45
SURI Sharpe Ratio Rank: 41
SURI Sortino Ratio Rank: 42
SURI Omega Ratio Rank: 39
SURI Calmar Ratio Rank: 57
SURI Martin Ratio Rank: 48

XPH

XPH Risk / Return Rank: 55
XPH Sharpe Ratio Rank: 51
XPH Sortino Ratio Rank: 51
XPH Omega Ratio Rank: 46
XPH Calmar Ratio Rank: 64
XPH Martin Ratio Rank: 63

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SURI vs. XPH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Simplify Propel Opportunities ETF (SURI) and SPDR S&P Pharmaceuticals ETF (XPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SURI	XPH	Difference
Sharpe ratio: Return per unit of total volatility	1.46	1.77	-0.32
Sortino ratio: Return per unit of downside risk	2.11	2.51	-0.40
Omega ratio: Gain probability vs. loss probability	1.26	1.30	-0.04
Calmar ratio: Return relative to maximum drawdown	2.81	3.19	-0.38
Martin ratio: Return relative to average drawdown	7.91	11.37	-3.46
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SURI vs. XPH - Sharpe Ratio Comparison

The current SURI Sharpe Ratio is 1.46, which is comparable to the XPH Sharpe Ratio of 1.77. The chart below compares the historical Sharpe Ratios of SURI and XPH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	SURI	XPH	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.46	1.77	-0.32
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.17	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.16	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.15	0.38	-0.23

Drawdowns

SURI vs. XPH - Drawdown Comparison

The maximum SURI drawdown since its inception was -47.76%, roughly equal to the maximum XPH drawdown of -48.03%. Use the drawdown chart below to compare losses from any high point for SURI and XPH.

Drawdown Indicators

	SURI	XPH	Difference
Max Drawdown Largest peak-to-trough decline	-47.76%	-48.03%	+0.27%
Max Drawdown (1Y) Largest decline over 1 year	-11.78%	-11.97%	+0.19%
Max Drawdown (3Y) Largest decline over 3 years	-47.76%	-23.57%	-24.19%
Max Drawdown (5Y) Largest decline over 5 years	—	-31.63%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-35.97%	—
Current Drawdown Current decline from peak	-17.46%	-7.22%	-10.24%
Average Drawdown Average peak-to-trough decline	-17.37%	-17.25%	-0.12%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.17%	3.35%	+0.82%

Volatility

SURI vs. XPH - Volatility Comparison

The current volatility for Simplify Propel Opportunities ETF (SURI) is 5.89%, while SPDR S&P Pharmaceuticals ETF (XPH) has a volatility of 7.03%. This indicates that SURI experiences smaller price fluctuations and is considered to be less risky than XPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SURI	XPH	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.89%	7.03%	-1.14%
Volatility (6M) Calculated over the trailing 6-month period	14.29%	16.77%	-2.48%
Volatility (1Y) Calculated over the trailing 1-year period	22.79%	21.52%	+1.27%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	28.27%	20.84%	+7.43%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	28.27%	22.10%	+6.17%

SURI vs. XPH - Expense Ratio Comparison

SURI has a 2.51% expense ratio, which is higher than XPH's 0.35% expense ratio.

Dividends

SURI vs. XPH - Dividend Comparison

SURI's dividend yield for the trailing twelve months is around 16.04%, more than XPH's 0.66% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
SURI Simplify Propel Opportunities ETF	16.04%	16.31%	21.41%	14.71%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
XPH SPDR S&P Pharmaceuticals ETF	0.66%	0.83%	1.58%	1.28%	1.64%	0.95%	0.47%	0.64%	0.65%	0.67%	0.63%	7.15%

Frequently Asked Questions

Can I hold both SURI and XPH in my portfolio?

SURI and XPH have a correlation of 0.53, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, SURI or XPH?

XPH has higher volatility (7.03%) compared to SURI (5.89%). In terms of maximum drawdown, SURI dropped -47.76% vs XPH's -48.03%.

Which ETF is better, SURI or XPH?

On 3-year performance, XPH leads with 13.07% vs 6.93% for SURI. On fees, XPH is cheaper at 0.35% per year. On volatility, SURI has been the lower-risk option at 5.89%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, SURI or XPH?

Over the 3-year period, XPH has performed better with a 13.07% return vs 6.93%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, SURI or XPH?

XPH is cheaper with a 0.35% expense ratio, compared with 2.51% for SURI.

Which ETF pays a higher dividend yield, SURI or XPH?

SURI has the higher dividend yield at 16.04%, compared with 0.66% for XPH.

What is the main difference between SURI and XPH?

They also come from different issuers: Simplify and State Street. Their fees differ too: 2.51% for SURI and 0.35% for XPH.

Which has better risk-adjusted returns?

XPH currently has the higher Sharpe Ratio (1.77 vs 1.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.